BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tomasoni D, Adamo M, Anker MS, von Haehling S, Coats AJS, Metra M. Heart failure in the last year: progress and perspective. ESC Heart Fail. 2020;. [PMID: 33277825 DOI: 10.1002/ehf2.13124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Tomasoni D, Vishram-Nielsen JKK, Pagnesi M, Adamo M, Lombardi CM, Gustafsson F, Metra M. Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care. ESC Heart Fail 2022. [PMID: 35352499 DOI: 10.1002/ehf2.13859] [Reference Citation Analysis]
2 Pascual-Figal D, Bayés-Genis A, Beltrán-Troncoso P, Caravaca-Pérez P, Conde-Martel A, Crespo-Leiro MG, Delgado JF, Díez J, Formiga F, Manito N. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Front Cardiovasc Med 2021;8:754499. [PMID: 34859070 DOI: 10.3389/fcvm.2021.754499] [Reference Citation Analysis]
3 Tomasoni D, Adamo M, Metra M. March 2022 at a glance: focus on medical therapy, prevention and comorbidities. Eur J Heart Fail 2022;24:403-5. [PMID: 35384200 DOI: 10.1002/ejhf.2226] [Reference Citation Analysis]
4 Usuda D, Higashikawa T, Hotchi Y, Usami K, Shimozawa S, Tokunaga S, Osugi I, Katou R, Ito S, Yoshizawa T, Asako S, Mishima K, Kondo A, Mizuno K, Takami H, Komatsu T, Oba J, Nomura T, Sugita M. Angiotensin receptor blocker neprilysin inhibitors. World J Cardiol 2021; 13(8): 325-339 [PMID: 34589168 DOI: 10.4330/wjc.v13.i8.325] [Reference Citation Analysis]
5 Tomasoni D, Adamo M, Metra M. January 2021 at a glance: focus on sex differences, acute heart failure and exercise capacity. Eur J Heart Fail 2021;23:1-2. [PMID: 33725389 DOI: 10.1002/ejhf.1874] [Reference Citation Analysis]
6 Zhang X, Li T, Cheng HJ, Wang H, Ferrario CM, Groban L, Cheng CP. Chronic GPR30 agonist therapy causes restoration of normal cardiac functional performance in a male mouse model of progressive heart failure: Insights into cellular mechanisms. Life Sci 2021;285:119955. [PMID: 34520767 DOI: 10.1016/j.lfs.2021.119955] [Reference Citation Analysis]
7 Tomasoni D, Adamo M, Metra M. December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models. Eur J Heart Fail 2021;23:1993-4. [PMID: 34935252 DOI: 10.1002/ejhf.1896] [Reference Citation Analysis]
8 Du H, Li X, Zhao W, Jiang N, M.a B. The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure. Journal of Healthcare Engineering 2022;2022:1-8. [DOI: 10.1155/2022/9494981] [Reference Citation Analysis]
9 Wang C, Jian W, Luo Q, Cui J, Qing Y, Qin C, Li G, Chen W. Prognostic value of cartilage intermediate layer protein 1 in chronic heart failure. ESC Heart Fail 2021. [PMID: 34939356 DOI: 10.1002/ehf2.13746] [Reference Citation Analysis]
10 Lin Z, Wong LYF, Cheung BMY. Diuretic-induced hypokalaemia: an updated review. Postgrad Med J 2021:postgradmedj-2020-139701. [PMID: 33688065 DOI: 10.1136/postgradmedj-2020-139701] [Reference Citation Analysis]
11 Anghel L, Sascău R, Zota IM, Stătescu C. Well-Known and Novel Serum Biomarkers for Risk Stratification of Patients with Non-ischemic Dilated Cardiomyopathy. Int J Mol Sci 2021;22:5688. [PMID: 34073616 DOI: 10.3390/ijms22115688] [Reference Citation Analysis]
12 Usuda D, Higashikawa T, Hotchi Y, Usami K, Shimozawa S, Tokunaga S, Osugi I, Katou R, Ito S, Yoshizawa T, Asako S, Mishima K, Kondo A, Mizuno K, Takami H, Komatsu T, Oba J, Nomura T, Sugita M. Angiotensin receptor blocker neprilysin inhibitors. WJC 2021;13:326-40. [DOI: 10.4330/wjc.v13.i8.326] [Reference Citation Analysis]
13 Ai J, Shuai Z, Tang K, Li Z, Zou L, Liu M. Sacubitril/valsartan alleviates myocardial fibrosis in diabetic cardiomyopathy rats. Hellenic J Cardiol 2021:S1109-9666(21)00093-2. [PMID: 33957252 DOI: 10.1016/j.hjc.2021.04.004] [Reference Citation Analysis]
14 Tomasoni D, Adamo M, Anker MS, von Haehling S, Coats AJS, Metra M. Heart failure in the last year: progress and perspective. ESC Heart Fail. 2020;. [PMID: 33277825 DOI: 10.1002/ehf2.13124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
15 Matthews N, Pandolfo B, Moses D, Gentile C. Taking It Personally: 3D Bioprinting a Patient-Specific Cardiac Patch for the Treatment of Heart Failure. Bioengineering 2022;9:93. [DOI: 10.3390/bioengineering9030093] [Reference Citation Analysis]
16 Stretti L, Zippo D, Coats AJS, Anker MS, von Haehling S, Metra M, Tomasoni D. A year in heart failure: an update of recent findings. ESC Heart Fail 2021;8:4370-93. [PMID: 34918477 DOI: 10.1002/ehf2.13760] [Reference Citation Analysis]
17 Balan I, Khayo T, Sultanova S, Lomakina Y. Overview of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors for the Treatment of Non-diabetic Heart Failure Patients. Cureus 2021;13:e17118. [PMID: 34527497 DOI: 10.7759/cureus.17118] [Reference Citation Analysis]
18 Wang C, Qing Y, Chen W, Li G. A novel nutritional index as a predictor of mortality in dilated cardiomyopathy: a retrospective study. PeerJ 2022;10:e12704. [DOI: 10.7717/peerj.12704] [Reference Citation Analysis]
19 Saito H, Matsue Y, Maeda D, Kamiya K, Kagiyama N, Endo Y, Yoshioka K, Mizukami A, Minamino T. Arm lean mass measured using dual-energy X-ray absorptiometry to predict mortality in older patients with heart failure. Archives of Gerontology and Geriatrics 2022. [DOI: 10.1016/j.archger.2022.104689] [Reference Citation Analysis]